Valneva SE (VALN) Capital Expenditures (2021 - 2026)
Valneva SE (VALN) posted Capital Expenditures of -$289174.2 for Q1 2026, down 103.2% sequentially from $9.0 million in Q4 2025, and up 80.39% YoY from -$160303.6 in Q1 2025.
Valneva SE (VALN) Capital Expenditures (2021 - 2026) Analysis & Trends
Valneva SE has reported Capital Expenditures for 6 years, with the latest figure at -$289174.2 in Q1 2026.
- Quarterly Capital Expenditures rose 80.39% year-over-year to -$289174.2 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.5 million (down 63.7% YoY) and the FY2025 annual result came in at $5.1 million, down 65.71% from the prior year.
- Capital Expenditures declined to -$289174.2 in Q1 2026 per VALN's latest filing, from $9.0 million in the prior quarter.
- Over five years, Capital Expenditures peaked at $7.8 billion in Q3 2023 and troughed at -$7.8 billion in Q2 2023.
- A 5-year average of $3.6 million and a median of -$1.4 million in 2025 frame the typical range for Capital Expenditures.
- The widest YoY moves for Capital Expenditures: up 118555.13% in 2023, down 111166.8% in 2023.
- Over 5 years, Capital Expenditures stood at $52.8 million in 2022, then sank by 53.95% to $24.3 million in 2023, then grew by 4.97% to $25.5 million in 2024, then plunged by 64.61% to $9.0 million in 2025, then sank by 103.2% to -$289174.2 in 2026.
- According to Business Quant data, Capital Expenditures over the past three periods registered -$289174.2, $9.0 million, and -$780928.8 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Valneva SE | 618.67 Mn | 477.41 Mn | 1.86 Mn | 971,734.51 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 971,734.51 |
| Jun 30, 2026 | 971,734.51 |
| Mar 31, 2026 | -289,174.18 |
| Mar 31, 2026 | -289,174.18 |
| Dec 31, 2025 | 9.03 Mn |
| Dec 31, 2025 | 9.03 Mn |
| Sep 30, 2025 | -780,928.80 |
| Sep 30, 2025 | -780,928.80 |
| Jun 30, 2025 | -1.43 Mn |
| Jun 30, 2025 | -1.43 Mn |
| Mar 31, 2025 | -1.47 Mn |
| Mar 31, 2025 | -1.47 Mn |
| Dec 31, 2024 | 25.51 Mn |
| Dec 31, 2024 | 25.51 Mn |
| Sep 30, 2024 | -6.48 Mn |
| Sep 30, 2024 | -6.48 Mn |
| Jun 30, 2024 | 424,293.71 |
| Jun 30, 2024 | 424,293.71 |
| Mar 31, 2024 | -4.89 Mn |
| Mar 31, 2024 | -4.89 Mn |